Renoprotective Properties of Angiotensin Receptor Blockers beyond Blood Pressure Lowering
Open Access
- 1 December 2005
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 16 (12), 3631-3641
- https://doi.org/10.1681/asn.2005050522
Abstract
Clinical studies have demonstrated that some antihypertensive agents provide renoprotection independent of BP lowering. Recent in vitro and in vivo studies evaluated the mechanisms involved in this protection. First, the in vitro effects of several angiotensin II type 1 receptor blockers (ARB), calcium channel blockers (CCB), and β blockers (BB) on various mediators were compared: Formation of pentosidine (an advanced glycation end product), hydroxyl radical-induced formation of o-tyrosine, and transition metals–induced oxidation of ascorbic acid (the Fenton reaction). All of the six tested ARB but neither the six CCB nor the nine BB inhibited pentosidine formation. ARB, as well as BB but not CCB, inhibited hydroxyl radicals–mediated o-tyrosine formation. ARB but neither BB nor CCB inhibited efficiently transition metals–catalyzed oxidation of ascorbic acid. Second, the in vivo consequences for the kidney of these various in vitro effects were evaluated. Hypertensive, type 2 diabetic rats with nephropathy, SHR/NDmcr-cp, were given for 20 wk either olmesartan (ARB) or nifedipine (CCB), or atenolol (BB). Despite similar BP reduction, only ARB significantly reduced proteinuria and prevented glomerular and tubulointerstitial damage (mesangial activation, podocyte injury, tubulointerstitial injury, and inflammatory cell infiltration). It is interesting that only ARB prevented abnormal iron deposition in the interstitium, corrected chronic hypoxia, reduced expressions of heme oxygenase and p47phox (a subunit of NADPHoxidase), and inhibited pentosidine formation (which correlates well with proteinuria). These observations confirm unique renoprotective properties of ARB, independent of BP lowering but related to decreased oxidative stress (hydroxyl radicals scavenging and inhibition of the Fenton reaction), correction of chronic hypoxia, and inhibition of advanced glycation end product formation and of abnormal iron deposition. These benefits of ARB may contribute to the renoprotection observed beyond BP lowering.Keywords
This publication has 40 references indexed in Scilit:
- Imbalance of T-Cell Subsets in Angiotensin II–Infused Hypertensive Rats With Kidney InjuryHypertension, 2003
- Cytoprotective role of heme oxygenase (HO)-1 in human kidney with various renal diseasesKidney International, 2001
- Heme protein-induced chronic renal inflammation: Suppressive effect of induced heme oxygenase-1Kidney International, 2001
- Heme Oxygenase-1 Is Upregulated in the Kidney of Angiotensin II–Induced Hypertensive RatsHypertension, 2000
- Nephropathy in Patients with Type 2 Diabetes MellitusNew England Journal of Medicine, 1999
- Immunohistochemical Localization of Advanced Glycation End Products, Pentosidine, and Carboxymethyllysine in Lipofuscin Pigments of Alzheimer's Disease and Aged NeuronsBiochemical and Biophysical Research Communications, 1997
- Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis. Alpha-smooth muscle actin is a marker of mesangial cell proliferation.JCI Insight, 1991
- The p67-phox cytosolic peptide of the respiratory burst oxidase from human neutrophils. Functional aspects.JCI Insight, 1990
- Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritisKidney International, 1989
- Role of iron in postischemic renal injury in the ratKidney International, 1988